October 16-17, 2017  |  Orlando, Florida USA

An Official Satellite Event to the American Society of Human Genetics (ASHG) Annual Meeting

REQUEST A BROCHURE

Organized and Produced By

 

Featured Speakers

 

Gregory Armstrong, MD, Incident Manager, Emergency Operations Center, Centers for Disease Control

Mick Correll
, President, Genospace
Andy Faucett, MS, LGC, Professor, Director of Policy and Education, Geisinger Health System

Joni Rutter, Ph.D., Director of Scientific Programs, All of Us Research Program, Precision Medicine Initiative, National Institutes of Health
pmphoto.jpg pmphotoa.jpg quinnetal.jpg

Sponsor/Exhibit

► MULTIPLE NETWORKING OPPORTUNITIES Before, During and After the Summit
► ACCESS To A Contact List Of Highly Targeted Personalized Medicine Leaders
► PROMOTIONAL PLACEMENT Across A Variety Of Platforms
► ATTEND Conference Presentations Side By Side With Attendees
► BUILD Brand Awareness Within a Network of Key Organziations
MORE INFORMATION

About the Conference

One of the longest running conferences in the personalized/precision medicine space, Arrowhead's 9th Annual Personalized & Precision Medicine Conference is coming to Orlando, Florida on October 16th-17th as an official Satellite Event to the American Society of Human Genetics Annual Meeting. 
Nine years ago Arrowhead’s Personalized & Precision Medicine Conference focused almost exclusively on the one-on-one relationship between the pharmaceutical and diagnostic industries. Since then the field has evolved to include not just these bilateral relationships, but multi-stakeholder relationships that are now integral to the future of the field. The conference will present the latest research and trends propelling Precision Medicine into the future with a focus on innovations in R & D, technological developments, Precision Medicine advances in infectious disease, CNS and cardiovascular disease, patient/citizen involvement (the ‘quantified self’) and its impact advancing Precision Medicine, health and social well being.

Key Themes at This Year's Conference

R & D: Trends & Challenges in Diagnostics and Therapeutics
Rapidly advancing scientific, technological and societal developments enable us to now combine the best science with applications in real time, including data collection. The ability to quantify physiologies and genetic make-ups as well as patients using omics based and imaging technologies is increasing. Speakers and panelists will discuss how these disruptions are improving R&D.

Technologies Revolutionizing Precision Medicine
Technological innovations including but not limited to new computational platforms and methods, machine learning, digital imaging, medical decision support tools and their impact on improving our understanding of disease processes, detection, treatment and prevention will be discussed by experts and innovators.

Beyond Oncology: Infectious Disease, CNS Disorders and Cardiovascular Disease
Genomics and the related -omics are improving our understanding of the biological complexities and physiological processes involved in infectious, CNS and cardiovascular disease and therefore the ability of Precision Medicine to impact detection, treatment, prevention, and chronic care. Presenters will discuss key advances in these respective fields, and the success and challenges in implementing precision into clinical management.

Harnessing Big Data For Research & Clinical Application
Large-scale data analysis is transforming the way we diagnose, treat and prevent disease. This section addresses a range of challenges in improving the access, portability, sharing and storage of personal genomic data. Accessing ‘locked’ databases whose data is available only for a cost versus publically available data, is but one such challenge.

Patient Engagement, Empowerment & Ethical Issues
Speakers will discuss the powerful impact of patient engagement and the various ethical issues in ensuring that patients have access to their data, if they so choose, as well as to the diagnostics, treatments and management strategies they have helped to develop by sharing their personal data.

From Research to Clinical Adoption: Drivers, Barriers, and Designing Success Strategies
Implementing innovation in clinical medicine increasingly requires adoption by health care institutions. The adoption process has always been, and remains, a formidable challenge due to various factors including; institutional barriers, cost, lack of knowledge, skill or motivation. Speakers will discuss a range of drivers, barriers and possible solution strategies to expedite efficient and effective implementation of evidence based solutions.

Networking Opportunities

 
You will have multiple chances to network and meet with others in the field of personalized medicine during the conference. There will be an online networking tool available before the conference even begins!
Attendees will have the opportunity to meet other attendees through the following networking services:
► Our CONFERENCE NETWORKING SITE is online weeks prior to the event. Attendees can schedule one-on-one meetings prior to the conference and print out a schedule of meeting times during the conference.
► EXTENDED NETWORKING BREAKS. These will give attendees the chance to meet those with whom they many not have set up meetings.
► EVENING RECEPTION. This will give attendees the chance to mingle with other professionals after a day full of speakers, meetings, and thought-provoking topics.
► SPEAKER Q&A SESSIONS. This will afford attendees the opportunity to ask additional questions of our speakers.

Download Brochure

Speaking Opportunities

Sponsor/Exhibit Opportunities

Join Conference Mailing List

The Personalized/Precision Medicine Blog

The official blog of the Annual Personalized and Precision Medicine Conference provides readers with information, insight and analysis regarding the field of personalized and precision medicine, genomics, genomic interpretation and the evolution of healthcare in the post-genomic era.

Novartis, Pfizer and Thermo Fisher to Lead Panel Discussion on Developing a Universal Test NGS-Based Companion Diagnostic Designed to Support Multiple Drug Development Programs

In 2015, Novartis, Pfizer and Thermo Fisher Scientific announced a long-term partnership, with the hopes of accelerating the development and registration of several new non-small cell lung cancer (NSCLC) drugs. Over the past year, this collaboration has worked on developing and commercializing a multi-marker, universal next-generation sequencing oncology test that will serve as a companion diagnostic for NSCLC across multiple drug platforms. 
 
Executives from Novartis, Thermo Fisher and Pfizer will be leading a panel discussion at the 8th Annual Personalized and Precision Medicine Conference, taking place October 12-13, 2016 in San Francisco, CA.  For more information on the conference, visit: http://personalizedmedicinepartnerships.com. 
 
The three executives that will lead this panel discussion are:
Mark Stevenson, MBA, Executive VP and President of Life Science Solutions, Thermo Fisher
Anne-Marie Martin, Ph.D., Senior VP, Global Head of Precision Medicine, Novartis
Hakan Sakul, Ph.D., VP and Head of Diagnostics, Pfizer
 
As there is a growing demand for targeted therapies to replace the “one-size-fits-all” paradigm, stakeholders in the health care industry are looking to satisfy the ultimate goal of providing more personalized therapies and timely access to the appropriate clinical trials. With the continued use of next-generation sequencing, which allows for multiple genes to be simultaneously tested from a single sample, personalized and precision medicine are on the forefront of revolutionizing the health care industry.
 
The NGS-based companion diagnostic test for NSCLC is being developed using Thermo Fisher’s Ion PGM Dx System and Oncomine assays. Hakan Sakul commented on the collaboration, “the Thermo Fisher Scientific NGS panel is aligned with a number of our clinical development programs, providing us with an opportunity to accelerate the development of each of these potential therapies for NSCLC patients with targetable genetic alterations.”
 
Mark Stevenson of Thermo Fisher also commented that, “the potential to generate a paradigm shift through this agreement – from one test for one drug, to one test for multiple NSCLC therapies, represents a significant step forward in realizing the promise of precision medicine.” For more information on the collaboration, visit: http://news.thermofisher.com/press-release/life-technologies/thermo-fisher-scientific-signs-development-agreement-next-generation.
 
Rate this blog entry:
Syapse Founder Jonathan Hirsch to Present a New Vi...

Related Posts

Testimonials from Past Conferences

Being new to Pharmacogenomics and genetic testing, the conference was very informative. Definitely a learning experience.
Karla S. Muller, </strong>Billing Specialist<strong>, Frontier Toxicology
Karla S. Muller, Billing Specialist, Frontier Toxicology

Very valuable focused sessions that provide actionable content.
Michael Giske, Epic Sciences
Michael Giske, Epic Sciences

An excellent and valuable conference.
Michelle Chen, President, Rayner-Chen Advisory
Michelle Chen, President, Rayner-Chen Advisory

This was my first PPMC and I was absolutely pleased with it. It was an amazing opportunity to network with other companies that are breaking into the healthcare industry, create partnerships and share challenges and hardships and try to find a way around them.
Shelley Herek, Director of Sales, LifeMap Sciences
Shelley Herek, Director of Sales, LifeMap Sciences

An excellent conference that concentrates on the benefits and risks associated with the use of genetic information to provide personalized diagnostics and therapeutic options to the patient. Great coverage of social, practical and regulatory issues.
Glenn Braunstein, MD, Chief Medical Officer, Pathway Genomics
Glenn Braunstein, MD, Chief Medical Officer, Pathway Genomics

Best multiple perspective insider's view of what's involved in implementing precision medicine that I've encountered thus far.
Lee Watkins, Jr., Director of Bioinformatics and IT, Johns Hopkins University Institute of Genomic Medicine
Lee Watkins, Jr., Director of Bioinformatics and IT, Johns Hopkins University Institute of Genomic Medicine

Very well organized, relevant and extremely useful conference.
Igor Keselman, Chief Operating Officer, Quremedy
Igor Keselman, Chief Operating Officer, Quremedy

Speakers provided a lot of deep domain expertise in diagnostics, oncology, regulatory, and patents related to personalized medicine.
Gitte Pedersen, Chief Executive Officer, Genomic Expression
Gitte Pedersen, Chief Executive Officer, Genomic Expression

Who Attends

20/20 GeneSystems, Inc. | 55th Parallel, LLC | Abbott Molecular | Abraxis Bioscience | ActX | Affymetrix, Inc. | Agendia, Inc | AlliedPath, Inc. | Almac Diagnostics | Alpha Genomix | Amgen | AncestryDNA | Appistry | Apple Tree Partners | Applied Biosystems | Arsenal Capital Partners | AssureRx Health, Inc. | AstraZeneca Pharamceuticals | Asuragen | Athena Diagnostics | Atlantic Health | Aureon Laboratories | Axial Biotech | BCBST | BCM Technologies | BD Becton Dickinson | Berkeley HeartLab, Inc. | Bio-X Center, China Fudan University | BIOCRATES Life Sciences | Biodesix, Inc. | BioM GmbH BioMarker Strategies | bioMerieux, Inc. | BioNano Genomics, Inc. | Biostat Solutions | BioTrove Inc. | BNA | Boston Biomedical Consultants | Boston Cancer Policy Institute, Inc | Boston Healthcare Associates | Brigham and Women's Hospital | Bristol Myers Squibb | BSG Institute | Cancer Care Ontario | Cedar Associates, LLC | Cedars-Sinai Medical Center | Celera Diagnostics | Chamberlain Medical Enterprises, Inc | Charite Berlin | CHU Sainte-Justine Chulalongkorn University | CIRANO | Clemson | Cleveland Clinic | Clinical Reference Laboratory | Coimbra Genomics | Consultant Core Principle Solutions | Coriell Institute for Medical Research | Covington & Burling | Crescendo Bioscience | CTG | Current Partnering | Cylex Inc | Cynergene | Decatur Memorial Hospital | deCode Genetics | Deloitte Center for Health Solutions | DHCS | Diaceutics | Diamyd Medical AB | DiTherea, Inc. | DNA Direct | DNA Genotek | Duke University | Easton Associates | Eli Lilly and Company | Elsevier | Emerson College | EPEMED | Eurolab Clinik | European Commission | F. Hoffmann-La Roche | FDA | Foley and Hoag | Foley and Lardner | Forest Laboratories, Inc. | Foundation Medicine | Fox Chase Cancer Center | Frost & Sullivan | GE Heathcare | Gen-Probe Inc | GeneDX, Inc. | Genizon Biosciences | Génome Québec | Genome Web LLC | Genomic Health, Inc. | Genomic Healthcare Strategies | Gilead Sciences, Inc | GlaxoSmithKline | Google | Green Cross Reference Lab | Hackensack University Medical Center | Harvard Medical School | Health Canada | Health Discovery Corporation | Helix Health Advisors | HIAE HillCo Health | Hopital Jean Verdier | Houston Methodist Hospital Research Institute | Humana | Ibiomedtech | Ikaria Industry Canada | Interleukin Genetics | ITHW Inc. | Jackson Laboratory for Genomic Medicine | Johns Hopkins University | JWMS | Labceutics | LabCorp | Laboratorio Genesis-MANLAB | Landspitali - University of Iceland | Life Technologies | Lilly Oncology | LS Foresight Institute, Lund University | Main Line Ventures | Mass Medical Angels | Massachusetts General Hospital | Massachusetts Institute of Technology | Max Planck Innovation GmbH | Mayo Clinic | MD Anderson Cancer Center | Mead Johnson Nutrition | Medco Health Solutions, Inc | Medical College of Wisconsin | Medical Device Consultants | Medicine Professional Corp. Giampiero Bartolucci | MedImmune, LLC | MEI Molecular | Memorial Sloan Kettering Cancer Center | Merck & Co. | Metamark Genetics | Millennium Laboratories | Millennium Pharmaceuticals | MindSpec Inc. | Mission Health | MolecularMD | Morristown Medical Center | Mount Sinai Hospital | MPEG LA | Myriad Genetic Laboratories, Inc. | Myriad Genetics Inc. | National Human Genome Institute | National Institute of Standards & Technology | Nature Medicine | NCTR/FDA | NeoGenomics Laboratories | NephroGenex, Inc. | Neurosurgery / KUH NeuroCenter | New York Presbyterian - Columbia New York University | NIDDK, National Institutes of Health | Nigist Elleni Mohammed Memorial Hospital | NIH National Library of Medicine | NCBI NIH/NHGRI | Nodality | Norwegian University of Science and Technology | Ohio State University College of Medicine | Oncology Solutions, LLC | OncoMethylome Sciences | Onyx Pharmaceuticals | Ortho Clinical Diagnostics | OSI Pharmaceuticals | Pamlab, LLC | Partners Health Care Ctr for Personalized Genetic Medicine Partners Healthcare | Pearson Investment Co. | PerkinElmer Inc. | Permedx Consulting Ltd. | Pfizer | PGxHealth | PricewaterhouseCoopers | Proskauer Rose LLP | Proventys, Inc. | Qiagen Manchester | RainDance Technologies | Randox Laboratories Ltd | Redmile Group, LLC | Regeneron Pharmaceuticals, Inc. | Regis College | Roche Molecular Diagnostics Roche Palo Alto | Roche Products Ltd | Roswell Park Cancer Institute | Rowan-SOM | Saladax Biomedical Inc. | Sanford Health | sanofi-aventis | SBIR Development Center | NCI Science Translational Medicine | Scientia Advisors | Seoul National University Hospital | Seqster, Inc. | Siemens Venture Capital | Simmons and Simmons | Sinoptia | SK Telecom Social & Scientific Systems | Sterne, Kessler, Goldstein & Fox | Stony Brook University | Stradley Ronon Stevens & Young, LLP | Suez Canal University | Synergenz BioScience, Inc | Tethys Bioscience | TGen | The Critical Path Institute | The Houston Methodist Research Institiute | The Jackson Laboratory | The PROOF Centre | Therapak Corporation | Third Rock Ventures | Thunderbird School of Global Management | UCL Institute of Child Health | UnitedHealth Group | University of Chicago | University of Delaware | University of Iowa | University of Louisville | University of North Carolina | University of Pittsburgh | University of Toronto, St. Michael's Hospital | University of Virginia | Veridex | Virginia Commonwealth University | VirtualScopics Inc. | Washington Hospital Center | MedStar Health | XIFIN, Inc.

About Us

Our events give attendees a conference experience that encompasses learning, networking and professional growth. We strive to facilitate connections. At our events, attendees, speakers, sponsors and exhibitors have opportunities to network and then to utilize those connections to further their professional goals. At Arrowhead Publishers, our focus is on bringing life sciences industry professionals together to help move research forward. Learn more about us at www.arrowheadpublishers.com.

Contact Us

For general information about the conference, please contact us at:
 This email address is being protected from spambots. You need JavaScript enabled to view it.
 +866.945.0263
 +866.945.0263
 5780 Lincoln Drive, Suite 205, Edina, Minnesota 55436 USA